Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi,Florian Castet,Philipp K Haber,Roser Pinyol,Miguel Torres-Martin,Laura Torrens,Agavni Mesropian,Huan Wang,Marc Puigvehi,Miho Maeda,Wei Qiang Leow,Elizabeth Harrod,Patricia Taik,Jigjidsuren Chinburen,Erdenebileg Taivanbaatar,Enkhbold Chinbold,Manel Solé Arqués,Michael Donovan,Swan Thung,Jaclyn Neely,Vincenzo Mazzaferro,Jeffrey Anderson,Sasan Roayaie,Myron Schwartz,Augusto Villanueva,Scott L Friedman,Andrew Uzilov,Daniela Sia,Josep M Llovet
DOI: https://doi.org/10.1136/gutjnl-2021-325918
IF: 24.5
2022-02-23
Gut
Abstract:Objective We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
gastroenterology & hepatology